Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Interim results with Advanced Tissue Sciences' (ATS) Dermagraft "encouraging"

This article was originally published in Clinica

Executive Summary

Results with Advanced Tissue Sciences' Dermagraft for treatment of diabetic foot ulcers in the first half of some 200 patients to be enrolled in the US trial are "quite encouraging", says president and COO Dr Gail Naughton. The interim results are in line with those of an earlier pivotal trial in which complete wound healing was seen in 50% of Dermagraft patients with no recurrence of ulcers up to 14 months after treatment.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT094325

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel